BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
These 2 moon rovers used cameras and lasers to hunt for simulated water ice — and one looks like WALL-E - 27 Strange Devices to Make Your Party Stick Out!
- 3James Webb Space Telescope discovers a lemon-shaped exoplanet unlike anything seen before: 'What the heck is this?'
- 4Grasping Various Kinds of Local misdemeanors
- 5Dad issues urgent plea to find stem cell donor for his son
- 3 moms, 3 countries, 1 very familiar problem: Why child care costs still don't add up for families
- US healthcare spending soars to over $5 trillion in 2024
- NI economy losing momentum due to Iran crisis
- Vote In favor of Your Number one Cell phones
- NASA is shooting for the moon. A guide to the Artemis II mission
- Three arrested in Paris after attempted bomb attack outside Bank of America
- Popular Home Rug Series For You
- Plane Passenger Allegedly Includes ‘Bomb Threat’ in Hotspot Network Name, Forces Flight to Make Emergency Landing
- CDC's upcoming vote on hepatitis B vaccine could impact childhood immunization
